C08.0 Billable / specific Malignant neoplasm of submandibular gland
ICD-10-CM C08.0 identifies “Malignant neoplasm of submandibular gland” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 2: Neoplasms
Code-level instructions
Inclusion terms1
Malignant neoplasm of submaxillary gland
Inherited instructions
C08 · Malignant neoplasm of other and unspecified major salivary glands
Includes1
malignant neoplasm of salivary ducts
Excludes 11
malignant neoplasms of specified minor salivary glands which are classified according to their anatomical location
Excludes 22
Use additional code8
- code to identify:
- alcohol abuse and dependence (F10.-)
- exposure to environmental tobacco smoke (Z77.22)
- exposure to tobacco smoke in the perinatal period (P96.81)
- history of tobacco dependence (Z87.891)
- occupational exposure to environmental tobacco smoke (Z57.31)
- tobacco dependence (F17.-)
- tobacco use (Z72.0)
Chapters 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Official index references
Official index references (5)
Neoplasm, neoplastic (5)
- Neoplasm, neoplastic › salivary gland or duct(major) › submandibularNeoplasms
- Neoplasm, neoplastic › salivary gland or duct(major) › submaxillaryNeoplasms
- Neoplasm, neoplastic › submandibular glandNeoplasms
- Neoplasm, neoplastic › submaxillary gland or ductNeoplasms
- Neoplasm, neoplastic › Wharton's ductNeoplasms
History
Code history
Latest recorded change · FY2017
ChangedUnchanged
FY2017
Effective from
- Inherited rules changed
Malignant neoplasm of submandibular gland
Billable diagnosis code
CDC/NCHS · FY2017All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | Inherited rules changed |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Historical ICD-9 mappings · 2018
Historical mapping only; not an automatic code substitution.
- 142.1
This entry is a complete code in the selected edition. Reference checks do not establish clinical appropriateness or guarantee reimbursement.